Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(14-trans)-28-methylidene-2,3:14,15-dioxidoundecanorsqualene
(18E)-29-Methylidene-2,3-oxidohexanorsqualene
(18E)-29-methylidene-2,3-oxidosqualene
(18E)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
(18Z)-29-Methylidene-2,3-oxidohexanorsqualene
(18Z)-29-methylidene-2,3-oxidosqualene
(18Z)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
(2-trans)-1-methylidene-2,3-oxido-1'-norsqualene
(22E)-24-methylidene-30-nor-2,3-oxidosqualene
(22Z)-24-methylidene-30-nor-2,3-oxidosqualene
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-biphenyl-4-ylpropyl ether
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-phenylpropyl ether
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl hexyl ether
(3-trans-7E,11E,15E)-3,4:19,20-diepoxy-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraene
(3R,4S,7E)-15,16-epoxy-3-ethylthio-8,12,16-trimethyl-1,7,11-heptadecatrien-4-ol
(3R,4S,7E,11E)-15,16-epoxy-8,12,16-trimethyl-3-phenylthio-1,7,11-heptadecatrien-4-ol
(3R,4S,7E,11E,15E)-19,20-epoxy-3-ethylthio-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraen-4-ol
(4-Benzenesulfonyl-piperazin-1-yl)-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
(4-bromophenyl)[4-[6-(cyclopropylmethylmethylamino)hexyloxy]phenyl]methanone
-
IC50: 31.8 nM
(4-bromophenyl)[4-[6-[(3-hydroxypropyl)methylamino]-hexyloxy]phenyl]methanone
-
IC50: 15.7 nM
(4aalpha,5alpha,6alpha,8abeta)-Decahydro-5,8a-dimethyl-2-(1,5,9-trimethyldecyl)-6-isoquinolinol
-
and simplified analogues
(5E,9E)-13,14-epoxy-6,10,14-trimethyl-1-methylthio-1,5,9-pentadecatriene
(5E,9E,13E)-17,18-epoxy-5,10,14,18-tetramethyl-1-methylthio-1,5,9,13-nonadecatetraene
(5E,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-(trimethylsilylethynyl)tricosa-2,5,9,13,17-pentaene
-
+ (5Z,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-(trimethylsilylethynyl)tricosa-2,5,9,13,17-pentaene, IC50: 0.06 mM
(5E,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-vinyl-2,5,9,13,17-tricosapentaene
(5E,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
(5Z,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-(trimethylsilylethynyl)tricosa-2,5,9,13,17-pentaene
-
+ (5E,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-(trimethylsilylethynyl)tricosa-2,5,9,13,17-pentaene, IC50: 0.06 mM
(5Z,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
(6E,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
(6E,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene
(6Z)-10-aza-10,11-dihydrosqualene-2,3-epoxide
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-(2-methylthiovinyl)-2,6,10,14,18-tetracosapentaene
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
(6Z,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene
(Z)-3-[4-(4-bromobenzoyl)phenacylidene]quinuclidine
1,2-dilinoleoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
26% inhibition at 0.5 microM, no inhibition at 0.25 microM
1,2-dimyristoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
72% inhibition at 0.5 microM, 51% at 0.25 microM
1,2-dioleoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
57% inhibition at 0.5 microM, 42% at 0.25 microM
1,2-dipalmitoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
24% inhibition at 0.5 microM, 4% at 0.25 microM
1-(2-methyl-4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
1-(2-oxazolinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
87% inhibition at 0.001 mM
1-(2-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
8% inhibition at 0.001 mM
1-(2-thiazolinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
complete inhibition at 0.001 mM
1-(4-iodophenylsulfonyl)-4-(1-(4-pyridyl)piperidon-4-ylcarbonyl)piperazine
-
IC50: 82 nM
1-(4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
1-linolenoyl-2-palmitoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
26% inhibition at 0.5 microM, 5% inhibition at 0.25 microM
1-linoleoyl-2-linolenoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
45% inhibition at 0.5 microM, 18% at 0.25 microM
1-linoleoyl-2-myristoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
38% inhibition at 0.5 microM, 22% at 0.25 microM
1-linoleoyl-2-oleoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
31% inhibition at 0.5 microM, 8% at 0.25 microM
1-linoleoyl-2-palmitoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
27% inhibition at 0.5 microM, 3% at 0.25 microM
1-myristoyl-2-palmitoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
45% inhibition at 0.5 microM, 35% at 0.25 microM
1-oleoyl-2-linolenoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
29% inhibition at 0.5 microM, 7% at 0.25 microM
1-oleoyl-2-linoleoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
40% inhibition at 0.5 microM, 9% at 0.25 microM
1-oleoyl-2-palmitoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
46% inhibition at 0.5 microM, 24% at 0.25 microM
1-palmitoyl-2-linoleoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
20% inhibition at 0.5 microM, no inhibition at 0.25 microM
1-palmitoyl-2-oleoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
21% inhibition at 0.5 microM, 4% at 0.25 microM
1-[4-(trifluoromethoxy)phenylcarbonyl]-4-[4-(dimethylaminomethyl)phenylmeth yl]-piperazine
-
-
1-[4-chlorobenzyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylcarbonyl]-4-[4-(1-methyl-pyrazol-4-yl)phenylmethyl]-piperazine
-
inactive at 200 nM
1-[4-chlorophenylcarbonyl]-4-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenylmethyl]-piperazine
-
inactive at 200 nM
1-[4-chlorophenylcarbonyl]-4-[4-(dimethylaminomethyl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylcarbonyl]-4-[4-(imidazol-1-yl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylcarbonyl]-4-[4-(pyrazol-1-yl)phenylmethyl]-piperazine
-
inactive at 200 nM
1-[4-chlorophenylcarbonyl]-4-[4-(pyrazol-3-yl)phenylmethyl]-piperazine
-
inactive at 200 nM
1-[4-chlorophenylcarbonyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylsulfonyl]-4-[3-(pyridin-4-yl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylsulfonyl]-4-[4-(4-methylpiperazin-1-yl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylsulfonyl]-4-[4-(dimethylaminomethyl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylsulfonyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
-
-
1-[4-methoxyphenylcarbonyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
-
-
1-[4-trifluoroacetyl]-4-[4-(imidazol-1-yl)phenylmethyl]-piperazine
-
inactive at 200 nM
10,15-desdimethyl-2,3-oxidosqualene
-
-
10-desmethyl-2,3-oxidosqualene
-
-
18,19-dihydro-29-methylidene-2,3-oxidosqualene
-
IC50: 0.1 mM
18-heptanor-2,3-oxidosqualene
19-aza-18,19,22,23-tetrahydrosqualene-2,3-epoxide
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide N-oxide
19-Azasqualene-2,3-epoxide
2,2-dimethyl-3-[(3E,7E,11E,15E)-3,7,12,16,20-pentamethylhenicosa-3,7,11,15,19-pentaen-1-yl]aziridine
-
-
2,3,18,19-Dioxidosqualene stereoisomers
-
-
2,3-Epoxy-10-aza-10,11-dehydrosqualene
2-Aza-2,3-dihydrosqualene
2-aza-2,3-dihydrosqualene alcohol
-
-
2-Aza-2,3-dihydrosqualene N-oxide
2-[(4E,8E)-12,13-epoxy-5,9,13-trimethyl-4,8-tetradecadienylidene]-1,3-dithiane
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-benzodithiole
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-dithiane
2-[(4E,8E,12E,16E)-20,21-epoxy-4,8,13,17,21-pentamethyl-4,8,12,16-docosatetraenylidene]-1,3-dithiane
22,23-Epoxy-2-aza-2,3-dihydrosqualene
-
slight
22,23-epoxy-2-aza-2,3-dihydrosqualene-N-oxide
-
0.01 mM, 14% inhibition
27,28-bisnoroxidosqualene
-
irreversible inhibition
29-methylidene-2,3-oxidohexanorsqualene
-
-
3-(3,7-Dimethyl-octadeca-3,7,11,15-tetraenyl)-2,2-dimethyl-oxirane
3-(biphenyl-4-yloxy)-N,N-dimethylpropan-1-amine
3-beta-(beta-dimethylaminoethoxy)-androst-5en-17one
3-carboxy-4-nitrophenyldithio-1,1',2-tris-nor-squalene
-
-
3-[(4-chlorobenzoyl)-4-phenoxy]quinuclidin-3-ol
3-[(4-chlorobenzoyl)-4-phenoxy]quinuclidine
3-[2-(4-bromobenzophenone)ethynyl]quinuclidin-3-ol
3-[Methyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-amino]-propan-1-ol
-
0.01 mM, 2% inhibition
3beta-(2-diethylaminoethoxy)androst-5-en-17-one hydrochloride
-
U18666A
4,4,10beta-trimethyl-trans-decal-3beta-ol
-
specific inhibitor
4-(4-bromobenzoyl)-1-(1-(4-pyridyl)piperidin-4-ylcarbonyl)piperazine
-
96% inhibition at 0.001 mM
4-(4-bromophenylmethyl)-1-(1-(4-pyridyl)piperidin-4-ylcarbonyl)piperazine
-
complete inhibition at 0.001 mM
4-chloro-N-(4-{4-[(dimethylamino)methyl]phenyl}cyclohexyl)-N-methylbenzamide
-
BIBX 79
6-desmethyl-2,3-oxidosqualene
-
-
7-(4-allylmethylamino-but-2-ynyloxy)chromen-2-one
7-(morpholinyl-N-hexyloxy)chromen-2-one
7-(morpholinyl-N-octanyloxy)chromen-2-one
7-(piperidinyl-N-hexyloxy)chromen-2-one
7-[10-(allylmethylamino)-decyloxy]chromen-2-one
7-[4'-(N-diethylamino)-but-2-ynyloxy]chromen-2-one
7-[4'-(N-pyrrolidyn)-but-2-ynyloxy]chromen-2-one
7-[6-(allylmethylamino)-hexyloxy]-chromen-2-one
7-[8'(dimethylamino-N-octyloxy)]chromen-2-one
allyl-6-[4-(4-bromophenyl)-1H-benzo[d][1,2]oxazin-7-yloxy]hexylmethylamine
-
IC50: 4.1 nM
allyl[6-[1-(4-bromophenyl)-3,4-dihydroisoquinolin-6-yloxy]hexyl]methylamine
-
IC50: 7.9 nM
allyl[6-[1-(4-bromophenyl)isoquinolin-6-yloxy]hexyl]methylamine
-
IC50: 3.5 nM
allyl[6-[3-(4-bromophenyl)-1-methyl-1H-indazol-6-yloxy]hexyl]methylamine
-
IC50: 19.6 nM
allyl[6-[3-(4-bromophenyl)benzo[b]thiophen-6-yloxy]hexyl]methylamine
-
IC50: 5.6 nM
allyl[6-[3-(4-bromophenyl)benzo[d]isothiazol-6-yloxy]hexyl]methylamine
-
IC50: 2.9 nM
allyl[6-[4-(4-bromophenyl)-2H-chromen-7-yloxy]hexyl]methylamine
-
IC50: 11.4 nM
allyl[6-[4-(4-bromophenyl)quinazolin-7-yloxy]hexyl]methylamine
-
IC50: 12.3 nM
allyl[6-[4-(6-bromo-1,1-dioxobenzo[d]isothiazol-3-yl)phenoxy]hexyl]methylamine
-
IC50: 7.8 nM
azasqualene alcohol
-
0.01 mM, 13% inhibition
azasqualene alcohol N-oxide
dehydrocostus lactone
-
isolated from Laurus nobilis extract, 22% inhibition at 0.25 mM, 63% inhibition at 0.5 mM
diethyl dicarbonate
-
maximal inactivation at neutral pH, ´reactivation by hydroxylamine
diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-aminoxide
Diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
dodecyl-maleimide
-
mutant C457D shows 41.6% inhibition at 1 mM, 10.0% at 0.2 mM, and 7.2% at 0.025 mM, mutant C457D/E526A shows 9.0% inhibition at 0.2 mM and 0.0% at 0.025 mM, mutant C457D/A525C shows 86.0% inhibition at 1 mM, 30.5% at 0.2 mM, and 1.0% at 0.025 mM, mutant C457D/E526C shows 89.6% inhibition at 0.2 mM, 74.7% at 0.025 mM, and 45.1% at 0.01 mM
eremanthine
-
isolated from Laurus nobilis extract, 12% inhibition at 0.25 mM, 70% inhibition at 0.5 mM
ethanol extract from Angelica keiskei leaves
-
11% inhibition at 0.3 mg/ml
-
ethanol extract from Basella rubra leaves
-
5% inhibition at 0.3 mg/ml
-
ethanol extract from Chrysanthemum morifolium flowers
-
13% inhibition at 0.3 mg/ml
-
ethanol extract from Chrysanthemum morifolium leaves
-
7% inhibition at 0.3 mg/ml
-
ethanol extract from Colocasia esculenta rhizomes
-
55% inhibition at 0.3 mg/ml
-
ethanol extract from Cryptotaenia japonica leaves
-
10% inhibition at 0.3 mg/ml
-
ethanol extract from Glycine max immature seeds
-
14% inhibition at 0.3 mg/ml
-
ethanol extract from Oenanthe stolonifera leaves
-
13% inhibition at 0.3 mg/ml
-
ethanol extract from Perilla frutescens leaves
-
5% inhibition at 0.3 mg/ml
-
ethanol extract from Petasites japonicus buds
-
6% inhibition at 0.3 mg/ml
-
ethanol extract from Zingiber officinale buds
-
14% inhibition at 0.3 mg/ml
-
ethanol extract from Zingiber officinale rhizomes
-
6% inhibition at 0.3 mg/ml
-
N,N-Diethylazasqualene
-
non-competitive
N,N-Diethylazasqualene N-oxide
-
competitive
N,N-dimethyl-N-(4-methylenebenzophenonyl)amine
-
IC50: 0.005 mM
N,N-Dimethylformamide
-
-
N-(1-Oxododecyl)-4alpha,10-dimethyl-8-aza-trans-decal-3beta-ol
-
potent, competitive
N-(2-methylenebenzophenonyl)pyridinium
-
IC50: 0.059 mM
N-(3-methylenebenzophenonyl)pyridinium bromide
-
IC50: 0.016 mM
N-(4-methylenebenzophenonyl)pyridinium bromide
-
IC50: 0.00079 mM
N-(Ethoxycarbonyl)-2-ethoxy-1,2-dihydroquinoline
-
slight
N-[(1,5,9)-Trimethyl-decyl]-4alpha,10-dimethyl-8-aza-decal-3beta-ol
-
strong
N-[2-(4-(3-dimethylaminomethylphenyl)phenyl)ethyl]-4-cyanobenzenesulfonamide
-
inactive at 200 nM
N-[2-(4-(4-((pyrrolidin-1-yl)methyl)phenyl)phenyl)ethyl]-4-chlorobenzenesulfonamide
-
-
N-[2-(4-(4-dimethylaminomethylphenyl)phenyl)ethyl]-4-cyanobenzenesulfonamide
-
-
N-[3-(1,1'-biphenyl-4-yloxy)propyl]-N,N-dimethylamine
-
IC50: 2500 nM
NaCl
-
at high concentrations
Sulfur-substituted squalene oxide analogues
-
trans-N-(4-(5-[ethyl-(2-hydroxy-ethyl)-amino]-pentyl)-cyclohexyl)-N-methyl-4-trifluoromethyl-benzenesulfonamide fumarate
-
RO0714565
Trimethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
[19-(3,3-Dimethyl-oxiranyl)-4,8,13,17-tetramethyl-nonadeca-4,8,12,16-tetraenyl]-dimethyl-amine
-
0.01 mM, 8% inhibition
[4'-(6-allyl-methyl-amino-hexyloxy)-2'-fluoro-phenyl]-(4-bromo-phenyl)-methanone fumarate
[4'-(6-allyl-methyl-amino-hexyloxy)-2'-fluoro-phenyl]-(4-bromophenyl)-methanone fumarate
-
Ro 48-8071
[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl](4-chlorophenyl)methanone
[4-(4-Bromo-benzenesulfonyl)-piperazin-1-yl]-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
[4-[6-(allylmethylamino)hexyloxy]-2-hydroxyphenyl](4-bromophenyl)methanone
-
IC50: 6.3 nM
[4-[6-(allylmethylamino)hexyloxy]-2-methoxyphenyl](4-bromophenyl)methanone
-
IC50: 4.6 nM
[4-[6-(allylmethylamino)hexyloxy]-2-methylaminophenyl](4-bromophenyl)methanone
-
IC50: 4.1 nM
[4-[6-(allylmethylamino)hexyloxy]-2-methylsulfanylphenyl](4-bromophenyl)methanone
-
IC50: 6.2 nM
[4-[6-(allylmethylamino)hexyloxy]phenyl](4-bromophenol)methanone
-
IC50: 5.4 nM
[4-[6-(allylmethylamino)hexyloxy]phenyl](4-nitrophenyl)methanone
-
IC50: 1.9 nM
[4-[6-(allylmethylamino)hexyloxy]phenyl]-(4-fluorophenyl)methanone
-
IC50: 6.7 nM
[4-[6-(allylmethylamino)hexyloxy]phenyl]phenylmethanone
-
IC50: 22.5 nM
[5-(4-(4-chloro-benzoyl)-3-fluoro-phenoxy)-pentyl]-methyl-propyl-ammonium fumarate
-
IC50: 49 nM
[6-[6-(allylmethylamino)hexyloxy]pyridin-3-yl](4-bromophenyl)methanone
-
IC50: 8.7 nM
[6-[6-(cyclopropylmethylamino)hexyloxy]phenyl](4-bromophenyl)methanone
-
IC50: 35.3 nM
{4-[4-(4,5-Dihydro-oxazol-2-yl)-benzylidene]-piperidin-1-yl}-(4-trifluoromethyl-phenyl)-methanone
-
IC50: 90 nM, complete inhibition at 0.001 nM
{4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl}-(4-chloro-phenyl)-methanone
(14-trans)-28-methylidene-2,3:14,15-dioxidoundecanorsqualene
-
IC50: 0.0015 mM
(14-trans)-28-methylidene-2,3:14,15-dioxidoundecanorsqualene
-
IC50: 0.0004 mM
(18E)-29-Methylidene-2,3-oxidohexanorsqualene
-
IC50: 0.0015 mM, irreversible; potent, irreversible
(18E)-29-Methylidene-2,3-oxidohexanorsqualene
-
IC50: 0.0035 mM, irreversible; potent, irreversible
(18E)-29-methylidene-2,3-oxidosqualene
-
IC50: 0.0015 mM
(18E)-29-methylidene-2,3-oxidosqualene
-
IC50: 0.0035 mM
(18E)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
-
IC50: 0.03 mM
(18E)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
-
IC50: 0.05 mM
(18Z)-29-Methylidene-2,3-oxidohexanorsqualene
-
IC50: 0.015 mM; potent, irreversible
(18Z)-29-Methylidene-2,3-oxidohexanorsqualene
-
IC50: 0.02 mM; potent, irreversible
(18Z)-29-methylidene-2,3-oxidosqualene
-
IC50: 0.001 mM
(18Z)-29-methylidene-2,3-oxidosqualene
-
IC50: 0.0004 mM
(18Z)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
-
IC50: 0.05 mM
(18Z)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
-
IC50: 0.06 mM
(2-trans)-1-methylidene-2,3-oxido-1'-norsqualene
-
IC50: 0.05 mM
(2-trans)-1-methylidene-2,3-oxido-1'-norsqualene
-
IC50: 0.1 mM
(22E)-24-methylidene-30-nor-2,3-oxidosqualene
-
IC50: above 0.1 mM
(22E)-24-methylidene-30-nor-2,3-oxidosqualene
-
IC50: above 0.1 mM
(22Z)-24-methylidene-30-nor-2,3-oxidosqualene
-
IC50: above 0.1 mM
(22Z)-24-methylidene-30-nor-2,3-oxidosqualene
-
IC50: above 0.1 mM
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-biphenyl-4-ylpropyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Saccharomyces cerevisiae, and Pneumocystis carinii enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-biphenyl-4-ylpropyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Saccharomyces cerevisiae, and human enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-biphenyl-4-ylpropyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Pneumocystis carini, and human enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-biphenyl-4-ylpropyl ether
-
comparison with inhibitory effect on Pneumocystis carinii, Saccharomyces cerevisiae, and human enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-phenylpropyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Saccharomyces cerevisiae, and Pneumocystis carinii enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-phenylpropyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Saccharomyces cerevisiae, and human enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-phenylpropyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Pneumocystis carini, and human enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-phenylpropyl ether
-
comparison with inhibitory effect on Pneumocystis carinii, Saccharomyces cerevisiae, and human enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl hexyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Saccharomyces cerevisiae, and Pneumocystis carinii enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl hexyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Saccharomyces cerevisiae, and human enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl hexyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Pneumocystis carini, and human enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl hexyl ether
-
comparison with inhibitory effect on Pneumocystis carinii, Saccharomyces cerevisiae, and human enzyme
(3-trans-7E,11E,15E)-3,4:19,20-diepoxy-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraene
-
IC50: 0.0015 mM
(3-trans-7E,11E,15E)-3,4:19,20-diepoxy-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraene
-
IC50: 0.0025 mM
(3R,4S,7E)-15,16-epoxy-3-ethylthio-8,12,16-trimethyl-1,7,11-heptadecatrien-4-ol
-
IC50: 0.025 mM
(3R,4S,7E)-15,16-epoxy-3-ethylthio-8,12,16-trimethyl-1,7,11-heptadecatrien-4-ol
-
IC50: 0.012 mM
(3R,4S,7E,11E)-15,16-epoxy-8,12,16-trimethyl-3-phenylthio-1,7,11-heptadecatrien-4-ol
-
IC50: 0.04 mM
(3R,4S,7E,11E)-15,16-epoxy-8,12,16-trimethyl-3-phenylthio-1,7,11-heptadecatrien-4-ol
-
IC50: 0.0075 mM
(3R,4S,7E,11E,15E)-19,20-epoxy-3-ethylthio-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraen-4-ol
-
IC50: 0.0025 mM
(3R,4S,7E,11E,15E)-19,20-epoxy-3-ethylthio-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraen-4-ol
-
IC50: 0.001 mM
(4-Benzenesulfonyl-piperazin-1-yl)-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
-
IC50: 143 nM
(4-Benzenesulfonyl-piperazin-1-yl)-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
-
IC50: 326 nM
(5E,9E)-13,14-epoxy-6,10,14-trimethyl-1-methylthio-1,5,9-pentadecatriene
-
IC50: 0.0015 mM
(5E,9E)-13,14-epoxy-6,10,14-trimethyl-1-methylthio-1,5,9-pentadecatriene
-
IC50: 0.005 mM
(5E,9E,13E)-17,18-epoxy-5,10,14,18-tetramethyl-1-methylthio-1,5,9,13-nonadecatetraene
-
IC50: 0.00005 mM
(5E,9E,13E)-17,18-epoxy-5,10,14,18-tetramethyl-1-methylthio-1,5,9,13-nonadecatetraene
-
IC50: 0.001 mM
(5E,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-vinyl-2,5,9,13,17-tricosapentaene
-
IC50: 0.018 mM
(5E,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-vinyl-2,5,9,13,17-tricosapentaene
-
IC50: 0.032 mM
(5E,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
-
+ (5Z,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene, IC50: 0.05 mM
(5E,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
-
+ (5Z,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene, IC50: 0.02 mM
(5Z,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
-
+ (5E,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene, IC50: 0.05 mM
(5Z,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
-
+ (5E,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene, IC50: 0.02 mM
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
-
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: 0.003 mM, at a protein concentration of 3 mg/ml
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
-
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
-
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: 0.0048 mM, at a protein concentration of 5 mg/ml
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
-
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: 0.005 mM, at a protein concentration of 2 mg/ml
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
-
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: 0.005 mM, at a protein concentration of 1 mg/ml
(6E,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
-
IC50: 0.005 mM
(6E,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
-
IC50: 0.004 mM
(6E,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene
-
+ (6Z,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene, IC50: 0.03 mM
(6E,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene
-
+ (6Z,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene, IC50: 0.03 mM
(6Z)-10-aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: above 0.1 mM, at a protein concentration of 3 mg/ml
(6Z)-10-aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: above 0.02 mM, at a protein concentration of 5 mg/ml
(6Z)-10-aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: above 0.1 mM, at a protein concentration of 2 mg/ml
(6Z)-10-aza-10,11-dihydrosqualene-2,3-epoxide
-
poor
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-(2-methylthiovinyl)-2,6,10,14,18-tetracosapentaene
-
IC50: 0.012 mM
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-(2-methylthiovinyl)-2,6,10,14,18-tetracosapentaene
-
IC50: 0.0022 mM
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
-
IC50: 0.001 mM
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
-
IC50: 0.0004 mM
(6Z,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene
-
+ (6E,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene, IC50: 0.03 mM
(6Z,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene
-
+ (6E,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene, IC50: 0.03 mM
(Z)-3-[4-(4-bromobenzoyl)phenacylidene]quinuclidine
-
IC50: 83 nM, oral and selective inhibition of cholesterol biosynthesis derived from enzyme inhibition
(Z)-3-[4-(4-bromobenzoyl)phenacylidene]quinuclidine
-
IC50: 124 nM, oral and selective inhibition of cholesterol biosynthesis derived from enzyme inhibition
1-(2-methyl-4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
IC50: 112 nM
1-(2-methyl-4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
76% inhibition at 0.001 mM, IC50: 398 nM
1-(4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
IC50: 37 nM
1-(4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
complete inhibition at 0.001 mM, IC50: 116 nM
18-heptanor-2,3-oxidosqualene
-
IC50: 0.07 mM
18-heptanor-2,3-oxidosqualene
-
IC50: 0.015 mM
19-aza-18,19,22,23-tetrahydrosqualene-2,3-epoxide
-
IC50: 0.022 mM, protein concentration of 3 mg/ml
19-aza-18,19,22,23-tetrahydrosqualene-2,3-epoxide
-
IC50: 0.0075 mM, protein concentration of 5 mg/ml
19-aza-18,19,22,23-tetrahydrosqualene-2,3-epoxide
-
IC50: 0.035 mM, at a protein concentration of 2 mg/ml
19-aza-18,19,22,23-tetrahydrosqualene-2,3-epoxide
-
IC50: 0.0015 mM
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide
-
-
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide
-
-
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide
-
-
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide
-
-
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide
-
noncompetitive
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide N-oxide
-
-
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide N-oxide
-
-
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide N-oxide
-
-
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide N-oxide
-
poor, competitive
19-Azasqualene
-
-
19-Azasqualene-2,3-epoxide
-
-
19-Azasqualene-2,3-epoxide
-
-
19-Azasqualene-2,3-epoxide
-
-
19-Azasqualene-2,3-epoxide
-
-
2,3-Epoxy-10-aza-10,11-dehydrosqualene
-
6E isomer strongly inhibits enzyme in both cell cultures and microsomes; weak inhibition by 6Z isomer
2,3-Epoxy-10-aza-10,11-dehydrosqualene
-
6E isomer strongly inhibits enzyme in both cell cultures and microsomes; 6Z isomer has no effect on microsomal enzyme
2-Aza-2,3-dihydrosqualene
-
0.01 mM, 70% inhibition; IC50: 6.5 mM
2-Aza-2,3-dihydrosqualene
-
-
2-Aza-2,3-dihydrosqualene
-
0.01 mM, 70% inhibition; IC50: 7.5 mM
2-Aza-2,3-dihydrosqualene
-
0.01 mM, 70% inhibition; IC50: 10 mM
2-Aza-2,3-dihydrosqualene
-
IC50: 2.3 mM, pig microsomes. IC50: 0.15 mM, solubilized enzyme
2-Aza-2,3-dihydrosqualene N-oxide
-
-
2-Aza-2,3-dihydrosqualene N-oxide
-
IC50: 3.7 mM
2-Aza-2,3-dihydrosqualene N-oxide
-
IC50: 16 mM
2-Aza-2,3-dihydrosqualene N-oxide
-
IC50: 7 mM, pig microsomes. IC50: 3.3 mM, solubilized enzyme
2-[(4E,8E)-12,13-epoxy-5,9,13-trimethyl-4,8-tetradecadienylidene]-1,3-dithiane
-
IC50: 0.0025 mM
2-[(4E,8E)-12,13-epoxy-5,9,13-trimethyl-4,8-tetradecadienylidene]-1,3-dithiane
-
IC50: 0.006 mM
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-benzodithiole
-
IC50: 0.0035 mM
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-benzodithiole
-
IC50: 0.012 mM
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-dithiane
-
IC50: 0.00017 mM
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-dithiane
-
IC50: 0.00035 mM
2-[(4E,8E,12E,16E)-20,21-epoxy-4,8,13,17,21-pentamethyl-4,8,12,16-docosatetraenylidene]-1,3-dithiane
-
IC50: 0.035 mM
2-[(4E,8E,12E,16E)-20,21-epoxy-4,8,13,17,21-pentamethyl-4,8,12,16-docosatetraenylidene]-1,3-dithiane
-
IC50: 0.1 mM
3-(3,7-Dimethyl-octadeca-3,7,11,15-tetraenyl)-2,2-dimethyl-oxirane
-
IC50: 0.0015 mM
3-(3,7-Dimethyl-octadeca-3,7,11,15-tetraenyl)-2,2-dimethyl-oxirane
-
IC50: 0.0035 mM
3-(biphenyl-4-yloxy)-N,N-dimethylpropan-1-amine
-
IC50: 0.016 mM
3-(biphenyl-4-yloxy)-N,N-dimethylpropan-1-amine
-
IC50: 280 nM
3-(biphenyl-4-yloxy)-N,N-dimethylpropan-1-amine
-
IC50: 750 nM
3-beta-(beta-dimethylaminoethoxy)-androst-5en-17one
-
DMAE-DHA
3-beta-(beta-dimethylaminoethoxy)-androst-5en-17one
-
DMAE-DHA
3-beta-(beta-dimethylaminoethoxy)-androst-5en-17one
-
DMAE-DHA
3-[(4-chlorobenzoyl)-4-phenoxy]quinuclidin-3-ol
-
-
3-[(4-chlorobenzoyl)-4-phenoxy]quinuclidin-3-ol
-
-
3-[(4-chlorobenzoyl)-4-phenoxy]quinuclidine
-
-
3-[(4-chlorobenzoyl)-4-phenoxy]quinuclidine
-
-
3-[(4-chlorobenzoyl)-4-phenoxy]quinuclidine
-
IC50: 160 nM
3-[2-(4-bromobenzophenone)ethynyl]quinuclidin-3-ol
-
-
3-[2-(4-bromobenzophenone)ethynyl]quinuclidin-3-ol
-
-
7-(4-allylmethylamino-but-2-ynyloxy)chromen-2-one
-
-
7-(4-allylmethylamino-but-2-ynyloxy)chromen-2-one
-
-
7-(4-allylmethylamino-but-2-ynyloxy)chromen-2-one
-
-
7-(morpholinyl-N-hexyloxy)chromen-2-one
-
-
7-(morpholinyl-N-hexyloxy)chromen-2-one
-
-
7-(morpholinyl-N-hexyloxy)chromen-2-one
-
-
7-(morpholinyl-N-octanyloxy)chromen-2-one
-
-
7-(morpholinyl-N-octanyloxy)chromen-2-one
-
-
7-(morpholinyl-N-octanyloxy)chromen-2-one
-
-
7-(piperidinyl-N-hexyloxy)chromen-2-one
-
-
7-(piperidinyl-N-hexyloxy)chromen-2-one
-
-
7-(piperidinyl-N-hexyloxy)chromen-2-one
-
-
7-[10-(allylmethylamino)-decyloxy]chromen-2-one
-
-
7-[10-(allylmethylamino)-decyloxy]chromen-2-one
-
-
7-[10-(allylmethylamino)-decyloxy]chromen-2-one
-
-
7-[4'-(N-diethylamino)-but-2-ynyloxy]chromen-2-one
-
-
7-[4'-(N-diethylamino)-but-2-ynyloxy]chromen-2-one
-
-
7-[4'-(N-diethylamino)-but-2-ynyloxy]chromen-2-one
-
-
7-[4'-(N-pyrrolidyn)-but-2-ynyloxy]chromen-2-one
-
-
7-[4'-(N-pyrrolidyn)-but-2-ynyloxy]chromen-2-one
-
-
7-[4'-(N-pyrrolidyn)-but-2-ynyloxy]chromen-2-one
-
-
7-[6-(allylmethylamino)-hexyloxy]-chromen-2-one
-
-
7-[6-(allylmethylamino)-hexyloxy]-chromen-2-one
-
-
7-[6-(allylmethylamino)-hexyloxy]-chromen-2-one
-
-
7-[8'(dimethylamino-N-octyloxy)]chromen-2-one
-
-
7-[8'(dimethylamino-N-octyloxy)]chromen-2-one
-
-
7-[8'(dimethylamino-N-octyloxy)]chromen-2-one
-
-
azasqualene alcohol N-oxide
-
IC50: 0.055 mM, at a protein concentration of 3 mg/ml
azasqualene alcohol N-oxide
-
IC50: 0.055 mM, at a protein concentration of 2 mg/ml
BIBB 515
-
-
cholesterol
-
an increased cholesterol level suppresses the expression of 2,3-oxidosqualene cyclase
cholesterol
-
an increased cholesterol level suppresses the expression of 2,3-oxidosqualene cyclase
diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-aminoxide
-
IC50: 1.5 mM
diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-aminoxide
-
IC50: 14 mM
Diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
-
IC50: 3.2 mM
Diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
-
IC50: 12.5 mM
Iminosqualene
-
-
KCl
-
0-0.1 M: activity decreases with increasing concentration of KCl in the presence of optimal concentrations of Triton X-100
KCl
-
at high concentrations
NEM
-
1 mM, 20% inhibition
NEM
-
following pseudo-first order kinetics
Ro 48-8071
-
IC50: 8.0 nM for the recombinant enzyme, IC50: 6.5 nM for the human liver enzyme
Ro48-8071
-
IC50: 22 nM
S23515
-
-
Squalene maleimide
-
-
Sulfur-substituted squalene oxide analogues
-
mechanism-based inhibition
-
Sulfur-substituted squalene oxide analogues
-
mechanism-based inhibition
-
Sulfur-substituted squalene oxide analogues
-
mechanism-based inhibition
-
Trimethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
-
IC50: 13.3 mM
Trimethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
-
IC50: 5.1 mM
U18666A
-
-
U18666A
-
produce cataract formation
[4'-(6-allyl-methyl-amino-hexyloxy)-2'-fluoro-phenyl]-(4-bromo-phenyl)-methanone fumarate
-
RO0488071
[4'-(6-allyl-methyl-amino-hexyloxy)-2'-fluoro-phenyl]-(4-bromo-phenyl)-methanone fumarate
-
RO0488071
[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl](4-chlorophenyl)methanone
-
IC50: 92 nM
[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl](4-chlorophenyl)methanone
-
IC50: 22 nM
[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl](4-chlorophenyl)methanone
-
IC50: 400 nM
[4-(4-Bromo-benzenesulfonyl)-piperazin-1-yl]-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
-
IC50: 161 nM
[4-(4-Bromo-benzenesulfonyl)-piperazin-1-yl]-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
-
IC50: 228 nM
{4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl}-(4-chloro-phenyl)-methanone
-
IC50: 4.6 nM
{4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl}-(4-chloro-phenyl)-methanone
-
IC50: 4.3 nM
{4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl}-(4-chloro-phenyl)-methanone
-
IC50: 71 nM
additional information
-
antifungal activity of lanosterol synthase inhibitors
-
additional information
-
3-alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl-sn-glycerol has no inhibitory effect
-
additional information
-
a high fat diet reduces OSC expression in the liver
-
additional information
-
oxidosqualene cyclase inhibitors as antimicrobial agents
-
additional information
-
-
-
additional information
-
no inhibition: cholesterol
-
additional information
-
oxidosqualene cyclase inhibitors as antimicrobial agents
-
additional information
-
no inhibition: EDTA, diethyldicarbonate, phenylmethylsulfonyl fluoride
-
additional information
-
in solutions of low ionic strength the enzyme polymerizes to an inactive form
-
additional information
-
oxidosqualene cyclase inhibitors as antimicrobial agents
-
additional information
-
oxidosqualene cyclase inhibitors as antimicrobial agents
-